Core Viewpoint - The company has decided to discontinue the development of emugrobart after two studies indicated that the drug did not meet its intended outcomes [1] Group 1 - The decision to halt emugrobart's development was influenced by the results of two studies [1]

Group 1: Trustpilot's Fine - Italy's Competition Authority fined Trustpilot €4 million ($4.61 million) for not adequately verifying the authenticity of reviews on its platform [1] - The fine was imposed due to misleading consumers about how Trustpilot's services operate [1] Group 2: Siemens and Investment Hesitation - Siemens reported that the ongoing Iran war has caused customers to hold back on new investments [2] - The company noted that rising prices for raw materials and energy are contributing to this hesitation [2]

Core Insights - Novartis will present over 20 abstracts from its immunology portfolio at the American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) [1][2][3] Immunology Portfolio Highlights - New data on Rhapsido (remibrutinib) will be presented, focusing on early symptom improvement in CSU patients, with significant changes in daily itch and hives severity scores observed as early as week 1 [2][4] - Long-term efficacy data for Cosentyx (secukinumab) will be shared, reinforcing its continuous use in HS and psoriasis, including a matched adjusted indirect comparison of its safety and flare prevention against bimekizumab [4][5] Key Abstracts - Notable abstracts include: - "Early symptom improvement with remibrutinib in chronic spontaneous urticaria" (Abstract 71668) [3] - "Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa" (Abstract 76852) [5] - "Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis" (Abstract 73859) [5] Commitment to Innovation - Novartis emphasizes its dedication to advancing science in immunology, aiming to provide relief for patients with autoimmune diseases through a robust pipeline and innovative treatments [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 7, 2026 [1] Group 1: Class Action Details - Investors who bought Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the prospects of its INO-3107 Biologics License Application [5] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]

Chugai fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the development of an experimental drug for certain diseases that cause muscle weakness https://t.co/GgkK8tor87 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials for relacorilant, claiming it was a strong support for their New Drug Application (NDA) to the FDA, while the FDA had raised concerns about the clinical evidence [5]. - The defendants indicated confidence in the NDA approval process, stating that relacorilant was "approaching approval," despite known risks that it might not be approved [5].

点击注册小程序 查看完整报告 特别申明： 您可点击今日推送内容的第1条查看 【平安银行（000001.SZ）】零售利润占比回升，不良率维持稳定——2025年年报点评 2025年平安银行营收、PPOP、归母净利润分别同比下降10.4%、4.2%，降幅较1-3Q分别走阔0.6、0.7pct。零售 利润贡献占比较上年呈现低位回升，未来随着业务发展基础进一步夯实，零售业务盈利贡献占比有望逐步修 复。 （王一峰/董文欣）2026-03-22 您可点击今日推送内容的第2条查看 【中信银行（601998.SH）】营收增速环比改善，分红率升至31.75%——2025年年报点评 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 今 日 聚 焦 【海外TMT】复盘英伟达GTC会后行情，对2026年AI算力投资布局有何启示？——海外科技观点更新 与 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Aldeyra securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Aldeyra [2]. Group 2: Regulatory Issues and Stock Performance - On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the FDA's announcement, Aldeyra's stock price dropped by $2.99 per share, a decline of 70.7%, closing at $1.24 per share on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Eli Lilly and Company is recognized as a strong investment opportunity, particularly with the launch of its weight-loss drug Zepbound, which will be available for self-pay at $299 per month for the 2.5 mg dose [1] Group 1: Product Launch and Pricing - Zepbound, a once-weekly injectable for adults with obesity or overweight-related conditions, will be available for self-pay starting at $299 per month [1][2] - A new savings card will allow eligible adults with a valid prescription to access the same pricing nationwide, although it is limited to the KwikPen format [2] Group 2: Access and Cost Reduction Initiatives - Eli Lilly received a boost from new Medicare and Medicaid services implementation details aimed at enhancing access to medications at lower costs [3] - With the new Medicare and Medicaid Services details, Zepbound and other medications will be available through Medicare Part D plans, capping out-of-pocket costs for beneficiaries at $50 a month, with cost-sharing limited to $245 a month before reaching the deductible [4] Group 3: Company Overview - Eli Lilly is a global pharmaceutical leader focused on developing medicines for diabetes, obesity, cancer, and immunological disorders, with notable products including Mounjaro and Zepbound [5]